The vascular response to the K+ channel inhibitor 4-aminopyridine in hypertensive rats

European Journal of Pharmacology

Volumn 466, Issue 3, 2003, Pages 301-310

  Berg, Torill ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Angiotensin AT1 receptor; Endothelin ETA receptor; Hypertension; K+ channel; Protein kinase C; Sympathetic system; Vascular tension

Indexed keywords

3 [4 [3 (3 METHOXY 5 METHYL 2 PYRAZINYLSULFAMOYL) 2 PYRIDYL]PHENYL] 2,2 DIMETHYLPROPIONIC ACID; 4 AMINOPYRIDINE; ALPHA 1 ADRENERGIC RECEPTOR; ANGIOTENSIN I; ATROPINE; CATECHOLAMINE; CYCLIC GMP; ENDOTHELIN A RECEPTOR ANTAGONIST; INDOMETACIN; LOSARTAN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; PHENTOLAMINE; PHOSPHOLIPASE C; POTASSIUM CHANNEL INHIBITOR; PRAZOSIN; PROPRANOLOL; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RESERPINE; SCOPOLAMINE; STAUROSPORINE; UNCLASSIFIED DRUG; YOHIMBINE;

ADRENALECTOMY; ADRENERGIC TRANSMISSION; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG ELIMINATION; DRUG INHIBITION; DRUG MECHANISM; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SPONTANEOUSLY HYPERTENSIVE RAT; STIMULUS RESPONSE; TENSION; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE;

EID: 0037453389     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01555-3     Document Type: Article

References (34)

1. Aiello E.A., Malcolm A.T., Walsh M.P., Cole W.C. Beta-adrenoceptor activation and PKA regulate delayed rectifier K+ channels of vascular smooth muscle cells. Am. J. Physiol. 275:1998;H448-H459.
2. Berg T. Analysis of the pressor response to the K(+) channel inhibitor 4-aminopyridine. Eur. J. Pharmacol. 452:2002;325-337.
3. Betts L.C., Kozlowski R.Z. Electrophysiological effects of endothelin-1 and their relationship to contraction in rat renal arterial smooth muscle. Br. J. Pharmacol. 130:2000;787-796.
4. Chen G.F., Cheung D.W. Characterization of acetylcholine-induced membrane hyperpolarization in endothelial cells. Circ. Res. 70:1992;257-263.
5. Clement-Chomienne O., Walsh M.P., Cole W.C. Angiotensin II activation of protein kinase C decreases delayed rectifier K+ current in rabbit vascular myocytes. J. Physiol. (Lond.). 495:1996;689-700.
6. Cox R.H., Folander K., Swanson R. Differential expression of voltage-gated K(+) channel genes in arteries from spontaneously hypertensive and Wistar-Kyoto rats. Hypertension. 37:2001;1315-1322.
7. Damsma G., Biessels P.T., Westerink B.H., De Vries J.B., Horn A.S. Differential effects of 4-aminopyridine and 2,4-diaminopyridine on the in vivo release of acetylcholine and dopamine in freely moving rats measured by intrastriatal dialysis. Eur. J. Pharmacol. 145:1988;15-20.
8. Du X.J., Cox H.S., Dart A.M., Esler M.D. Depression of efferent parasympathetic control of heart rate in rats with myocardial infarction: effect of losartan. J. Cardiovasc. Pharmacol. 31:1998;937-944.
9. Esler M.D. Catecholamines and essential hypertension. Bailliere's Clin. Endocrinol. Metab. 7:1993;415-438.
10. Gomez J.P., Ghisdal P., Morel N. Changes of the potassium currents in rat aortic smooth muscle cells during postnatal development. Pflügers Arch. 441:2000;388-397.
11. Huang H.Y., Zhou C.W. 3,4-Diaminopyridine facilitates norepinephrine release in chick sympathetic neurons. Zhongguo Yao Li Xue Bao. 16:1995;348-351.
12. Katovich M.J., Gelband C.H., Reaves P., Wang H.W., Raizada M.K. Reversal of hypertension by angiotensin II type 1 receptor antisense gene therapy in the adult SHR. Am. J. Physiol. 277:1999;H1260-H1264.
13. Kirpekar M., Kirpekar S.M., Prat J.C. Effect of 4-aminopyridine on release of noradrenaline from the perfused cat spleen by nerve stimulation. J. Physiol. (Lond.). 272:1977;517-528.
14. Kirpekar S.M., Prat J.C., Schiavone M.T. Effect of muscarine on release of catecholamines from the perfused adrenal gland of the cat. Br. J. Pharmacol. 77:1982;455-460.
15. Leander S., Arner A., Johansson B. Effects of 4-aminopyridine on mechanical activity and noradrenaline release in the rat portal vein in vitro. Eur. J. Pharmacol. 46:1977;351-361.
16. Lee S.B., Kim S.Y., Sung K.W. Cardiovascular regulation by cholinergic mechanisms in rostral ventrolateral medulla of spontaneously hypertensive rats. Eur. J. Pharmacol. 205:1991;117-123.
17. Lemeignan M., Millart H., Lamiable D., Molgo J., Lechat P. Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats. Brain Res. 304:1984;166-169.
18. Mark A.L. The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure. J. Hypertens. (Suppl. 14):1996;S159-S165.
19. + channels in genetic and nongenetic hypertension. Circ. Res. 79:1996;295-301.
20. + channel opener, cromromakalim. Br. J. Pharmacol. 97:1989;941-949.
21. Mistry D.K., Garland C.J. The influence of phenylephrine outward potassium currents in single smooth muscle cells from the rabbit mesenteric artery. Gen. Pharmacol. 33:1999;389-399.
22. Molgo J., Lundh H., Thesleff S. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur. J. Pharmacol. 61:1980;25-34.
23. Nagao T., Vanhoutte P.M. Hyperpolarization contributes to endothelium-dependent relaxations to acetylcholine in femoral veins of rats. Am. J. Physiol. 261:1991;H1034-H1037.
24. Paskov D.S., Agoston S., Bowman W.C. 4-aminopyridine hydrochloride (pymadin). Karckevich D.A. Handbook of Experimental Pharmacology. 1986;679-717 Springer, Berlin.
25. Rahn K.H., Barenbrock M., Hausberg M. The sympathetic nervous system in the pathogenesis of hypertension. J. Hypertens. 17(Suppl. 3):1999;S11-S14.
26. Sampson L.J., Plane F., Garland C.J. Involvement of cyclic GMP and potassium channels in relaxation evoked by the nitric oxide donor, diethylamine NONOate, in the rat small isolated mesenteric artery. Naunyn-Schmiedeberg's Arch. Pharmacol. 364:2001;220-225.
27. Sander M., Victor R.G. Neural mechanisms in nitric-oxide-deficient hypertension. Curr. Opin. Nephrol. Hypertens. 8:1999;61-73.
28. Sundaram K., Sapru H. Cholinergic nerve terminals in the ventrolateral medullary pressor area: pharmacological evidence. J. Auton. Nerv. Syst. 22:1988;221-228.
29. Tanno M., Tsuchida A., Nozawa Y., Matsumoto T., Hasegawa T., Miura T., Shimamoto K. Roles of tyrosine kinase and protein kinase C in infarct size limitation by repetitive ischemic preconditioning in the rat. J. Cardiovasc. Pharmacol. 35:2000;345-352.
30. Varagic V.M., Prostran M.S., Stepanovic S., Savic J., Vujnov S. Transmitter interactions in the central cholinergic control of blood pressure regulation. Drug Metab. Drug Interac. 9:1991;49-76.
31. + channels by endothelium-derived relaxing factors. Clin. Exp. Pharmacol. Physiol. 26:1999;180-184.
32. Wilson C., Hunt S.J., Tang E., Wright N., Kelly E., Palmer S., Heys C., Mellor S., James R., Bialecki R. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist. J. Pharmacol. Exp. Ther. 290:1999;1085-1091.
33. Yuan J.X., Aldinger A.M., Juhaszova M., Wang J., Conte J.V. Jr., Gaine S.P., Orens J.B., Rubin L.J. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation. 98:1998;1400-1406.
34. Zygmunt P.M., Edwards G., Weston A.H., Larsson B., Hogestatt E.D. Involvement of voltage-dependent potassium channels in the EDHF-mediated relaxation of rat hepatic artery. Br. J. Pharmacol. 121:1997;141-149.